Mercaptopurine

巯嘌呤

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameMercaptopurine
Drug Alias Namemercaptopurinum6-巯基嘌呤6巯基嘌呤6-Mercaptopurinemercaptopurine +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHypoxanthine-guanine phosphoribosyltransferase inhibitors
TargetsHypoxanthine-guanine phosphoribosyltransferase
Therapy Area/IndicationsCrohn DiseaseChoriocarcinomaLeukemia, Myelogenous, Chronic +[4] 
Global Approved IndicationsChoriocarcinomaLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaChoriocarcinomaLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Original Approved Country/TerritoryUnited States
Original Approved Date1953/09/11
Country/TerritoryUnited StatesPuerto RicoSouth Africa +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesStason Pharma
China Registration ClassN/A

Develop Information

Active CompaniesStason Pharmaceuticals IncNational Cancer InstituteNova Laboratories Ireland Ltd +[5] 
Inactive CompaniesMylan Pharmaceuticals IncTeva GtcNova Laboratories Ltd
Active IndicationsChoriocarcinomaLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsCrohn Disease

Other Information

ATC CodeL01BB02
Related LinksWikipediaDrugBankKEGG